#1 Clinical Trials Search in Europe

Mk-1084

MK-1084 is an investigational drug currently being studied in clinical trials for the treatment of advanced solid tumors, particularly those with KRAS G12C mutations. These trials are evaluating MK-1084 alone and in combination with other cancer therapies to assess its safety, efficacy, and how it behaves in the body. The studies involve patients with various types of advanced cancers, including non-small cell lung cancer.

Table of Contents

What is MK-1084?

MK-1084 is a new drug being developed for cancer treatment. It is currently undergoing clinical trials to evaluate its safety and effectiveness in treating various types of cancer, particularly those with a specific genetic mutation called KRAS G12C[1]. KRAS G12C is a change in the DNA of cancer cells that can make them grow and spread more quickly.

How does MK-1084 work?

MK-1084 is designed to target cancer cells with the KRAS G12C mutation. By specifically attacking these mutated cells, the drug aims to slow down or stop the growth of cancer while potentially causing fewer side effects than traditional chemotherapy, which affects both healthy and cancerous cells[1].

What conditions does MK-1084 treat?

MK-1084 is being studied for the treatment of several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. MK-1084 is being tested in patients with advanced or metastatic NSCLC (cancer that has spread to other parts of the body) who have the KRAS G12C mutation[2].
  • Advanced solid tumors: These are cancers that form solid masses in the body, such as in the lungs, colon, or breast. MK-1084 is being studied in patients with various types of advanced solid tumors that have the KRAS G12C mutation[1].

How is MK-1084 administered?

MK-1084 is taken orally, usually in the form of tablets or capsules[3]. The exact dosing schedule may vary depending on the specific clinical trial or treatment plan. In some studies, MK-1084 is given once daily, while in others, it may be combined with other cancer treatments[1].

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to study MK-1084. These trials are investigating various aspects of the drug, including:

  • Safety and effectiveness: Researchers are studying how well MK-1084 works in treating cancer and what side effects it may cause[1].
  • Combination therapy: Some trials are testing MK-1084 in combination with other cancer treatments, such as pembrolizumab (an immunotherapy drug)[2].
  • Pharmacokinetics: This involves studying how the body processes MK-1084, including how it’s absorbed, distributed, and eliminated from the body[4].
  • Drug interactions: Researchers are investigating how MK-1084 interacts with other medications, such as itraconazole (an antifungal drug) and phenytoin (an anti-seizure medication)[5].

Potential Side Effects and Safety

As MK-1084 is still in the research phase, its full safety profile is not yet known. However, clinical trials are carefully monitoring for any adverse events (side effects) that participants may experience[3]. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in appetite. The ongoing trials will help determine the specific side effects associated with MK-1084.

Future Prospects

MK-1084 shows promise in the treatment of cancers with the KRAS G12C mutation, particularly in non-small cell lung cancer. If the ongoing clinical trials demonstrate that MK-1084 is safe and effective, it could become an important new option for cancer patients[2]. The drug’s ability to target specific cancer mutations may lead to more personalized and potentially more effective cancer treatments in the future.

Aspect Details
Drug Name MK-1084
Administration Oral tablet or capsule
Target Population Patients with advanced solid tumors, particularly those with KRAS G12C mutations
Cancer Types Studied Non-small cell lung cancer (NSCLC), other advanced/metastatic solid tumors
Study Types Phase 1, Phase 1b, Phase 3 clinical trials
Treatment Approaches Monotherapy, combination with pembrolizumab, combination with chemotherapy
Primary Outcomes Safety, tolerability, pharmacokinetics, efficacy
Secondary Outcomes Objective response rate, duration of response, quality of life measures
Key Measurements Drug concentration in blood, tumor response, adverse events
Study Duration Varies by trial, up to approximately 56 months

FAQ

  • What is MK-1084? MK-1084 is an investigational drug being studied for the treatment of advanced solid tumors, particularly those with KRAS G12C mutations. It is taken orally as a tablet or capsule.
  • What types of cancer is MK-1084 being studied for? MK-1084 is being studied primarily for advanced solid tumors, including non-small cell lung cancer (NSCLC) with KRAS G12C mutations. Some trials are also looking at its effects on other types of advanced or metastatic solid tumors.
  • How is MK-1084 given to patients in clinical trials? In the clinical trials, MK-1084 is typically given as an oral tablet or capsule that patients take daily. The exact dosing regimen may vary between different studies.
  • Is MK-1084 being studied alone or with other treatments? MK-1084 is being studied both as a single agent (monotherapy) and in combination with other cancer treatments. Some combinations being tested include MK-1084 with pembrolizumab, chemotherapy drugs, and other targeted therapies.
  • What are the main goals of the MK-1084 clinical trials? The main goals of the MK-1084 clinical trials are to evaluate its safety, determine how it behaves in the body (pharmacokinetics), assess its effectiveness against tumors, and determine the optimal dosing. Researchers are also looking at potential side effects and how well patients tolerate the treatment.

Ongoing Clinical Trials on Mk-1084

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Greece Hungary +5

  • A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany Greece Hungary Italy Poland Spain

  • A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

    Recruiting

    2 1 1 1
    Investigated drugs:
    Finland Italy The Netherlands Poland Spain

  • A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Greece Italy Norway +3

  • Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Finland France Germany Hungary Italy The Netherlands +3

Glossary

  • KRAS G12C mutation: A specific genetic change in the KRAS gene that can drive cancer growth, particularly in some lung and colorectal cancers. MK-1084 is designed to target cancers with this mutation.
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all cases. It's one of the main cancer types being studied in MK-1084 trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. PK studies help determine the best dosing for a medication.
  • Monotherapy: Treatment using a single drug on its own, without combining it with other therapies.
  • Combination therapy: Treatment that uses two or more drugs or treatment methods together to target cancer.
  • Pembrolizumab: An immunotherapy drug that helps the immune system recognize and attack cancer cells. It's being studied in combination with MK-1084 in some trials.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent increasing the dose or that require a change in the dosing schedule.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.

References

  1. https://clinicaltrials.gov/study/NCT05067283
  2. https://clinicaltrials.gov/study/NCT06345729
  3. https://clinicaltrials.gov/study/NCT06619314
  4. https://clinicaltrials.gov/study/NCT06687759
  5. https://clinicaltrials.gov/study/NCT06719557